NO950424L - Benzoksazinoner som inhibitorer av HIV reverstranskriptase - Google Patents

Benzoksazinoner som inhibitorer av HIV reverstranskriptase

Info

Publication number
NO950424L
NO950424L NO950424A NO950424A NO950424L NO 950424 L NO950424 L NO 950424L NO 950424 A NO950424 A NO 950424A NO 950424 A NO950424 A NO 950424A NO 950424 L NO950424 L NO 950424L
Authority
NO
Norway
Prior art keywords
reverse transcriptase
benzoxazinones
hiv
inhibitors
hiv reverse
Prior art date
Application number
NO950424A
Other languages
English (en)
Other versions
NO950424D0 (no
NO304886B1 (no
Inventor
Steven D Young
Susan F Britcher
Linda S Payne
Lekhanh O Tran
Jr William Carl Lumma
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO950424(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO950424D0 publication Critical patent/NO950424D0/no
Publication of NO950424L publication Critical patent/NO950424L/no
Publication of NO304886B1 publication Critical patent/NO304886B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO950424A 1992-08-07 1995-02-06 Benzoksazinoner som inhibitorer av HIV-revers transkriptase NO304886B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92660792A 1992-08-07 1992-08-07
US5480593A 1993-04-27 1993-04-27
PCT/US1993/007376 WO1994003440A1 (en) 1992-08-07 1993-08-06 Benzoxazinones as inhibitors of hiv reverse transcriptase

Publications (3)

Publication Number Publication Date
NO950424D0 NO950424D0 (no) 1995-02-06
NO950424L true NO950424L (no) 1995-04-06
NO304886B1 NO304886B1 (no) 1999-03-01

Family

ID=26733517

Family Applications (3)

Application Number Title Priority Date Filing Date
NO950424A NO304886B1 (no) 1992-08-07 1995-02-06 Benzoksazinoner som inhibitorer av HIV-revers transkriptase
NO2000004C NO2000004I1 (no) 1992-08-07 2000-06-16 Efavirenz, eventuelt i form av et farmasøytisk akseptabelt salt
NO2008008C NO2008008I1 (no) 1992-08-07 2008-06-12 Kombinasjon av efavirenz, emtricitabin eller farmasoytisk akseptabelt salt eller ester derav, og tenofovir eller farmasoytisk akseptabelt prolegemiddel, salt eller ester derav, saerling tenofovirdisoproksilfumarat

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2000004C NO2000004I1 (no) 1992-08-07 2000-06-16 Efavirenz, eventuelt i form av et farmasøytisk akseptabelt salt
NO2008008C NO2008008I1 (no) 1992-08-07 2008-06-12 Kombinasjon av efavirenz, emtricitabin eller farmasoytisk akseptabelt salt eller ester derav, og tenofovir eller farmasoytisk akseptabelt prolegemiddel, salt eller ester derav, saerling tenofovirdisoproksilfumarat

Country Status (37)

Country Link
EP (1) EP0582455B1 (no)
JP (1) JPH0780860B2 (no)
KR (1) KR100272387B1 (no)
CN (3) CN1318031C (no)
AT (1) ATE197295T1 (no)
AU (1) AU670300B2 (no)
BG (1) BG62612B1 (no)
CA (1) CA2101572C (no)
CZ (1) CZ290447B6 (no)
DE (4) DE10199013I1 (no)
DK (1) DK0582455T3 (no)
DZ (1) DZ1707A1 (no)
ES (1) ES2151897T3 (no)
FI (1) FI115457B (no)
GR (1) GR3034754T3 (no)
HK (1) HK1009267A1 (no)
HR (1) HRP931102B1 (no)
HU (1) HU223076B1 (no)
IL (1) IL106507A (no)
LU (2) LU90709I2 (no)
LV (1) LV12719B (no)
MX (1) MX192812B (no)
MY (1) MY109834A (no)
NL (2) NL300032I2 (no)
NO (3) NO304886B1 (no)
NZ (1) NZ255216A (no)
PL (2) PL175615B1 (no)
PT (1) PT582455E (no)
RO (1) RO113641B1 (no)
RU (1) RU2186775C2 (no)
SG (1) SG52698A1 (no)
SI (1) SI9300419B (no)
SK (1) SK282276B6 (no)
TW (2) TWI233436B (no)
UA (1) UA42699C2 (no)
WO (1) WO1994003440A1 (no)
YU (1) YU49439B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
US6147210A (en) * 1996-07-26 2000-11-14 Dupont Pharmaceuticals Company Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
WO1998004535A1 (en) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcriptase inhibitors
US5932726A (en) * 1996-12-16 1999-08-03 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
ZA9711256B (en) 1996-12-16 1999-06-15 Du Pont Merck Pharma Asymmetric synthesis of benzoxazinones
PL197740B1 (pl) * 1997-02-05 2008-04-30 Merck & Co Inc Postać krystaliczna I (-)-6-chloro-4-cyklopropyloetynylo-4-trifluorometylo-1,4-dihydro-2H-3,1-benzoksazyn-2-onu i sposób krystalizacji postaci I (-)-6-chloro-4-cyklopropylo-etynylo-4-trifluorometylo-1,4-dihydro-2H-3,1-benzoksazyn-2-onu
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
CA2285000A1 (en) * 1997-04-07 1998-10-15 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones via new intermediates
US6124302A (en) 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
US5952528A (en) * 1997-09-03 1999-09-14 Merck & Co., Inc. Process for enhancing the optical purity
JP4157272B2 (ja) * 1997-09-03 2008-10-01 メルク エンド カムパニー インコーポレーテッド ２ｒ−［１−ヒドロキシ−１−トリフルオロメチル−３−シクロプロピルプロピン−２−イル］−４−クロロアニリンの光学純度を高める方法
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
US6673372B1 (en) 1998-06-11 2004-01-06 Bristol-Myers Squibb Pharma Company Crystalline Efavirenz
EP1091939A1 (en) * 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
WO2002081456A1 (en) 2001-03-28 2002-10-17 Bristol-Myers Squibb Company Cyanamide, alkoxyamino, and urea derivatives of 4, 4-disubstituted-3, 4-dihydro-2 (1h)- quinazolinones as hiv reverse transcriptase inhibitors
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
ES2549084T3 (es) * 2007-10-05 2015-10-22 Msd K.K. Derivados de benzoxazinona
GB0720503D0 (en) 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
EP2448917A2 (de) 2009-07-03 2012-05-09 Archimica GmbH Verfahren zur enantioselektiven addition von organometallischen kohlenstoffnukleophilen an trifluormethylketone und verwendung des verfahrens in der synthese von hiv reverse transcriptase inhibitoren
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103664816B (zh) * 2011-01-06 2016-03-02 中国科学院上海有机化学研究所 Hiv逆转录酶抑制剂依法韦伦类化合物的一锅法不对称合成工艺
CN102675125B (zh) * 2011-03-15 2015-02-18 中国科学院上海有机化学研究所 一种4-氯-2-三氟乙酰基苯胺及其类似物的简便高效合成方法
JP7071036B2 (ja) 2019-02-15 2022-05-18 福建永晶科技股▲ふん▼有限公司 Ｆｒｉｅｄｅｌ－Ｃｒａｆｔｓ反応の新しい新方法及び当該方法に用いられる触媒
CN110372625B (zh) * 2019-08-06 2022-11-01 常州大学 蓝光照射制备4-烷甲基-4-芳基-1,3-苯并噁嗪-2(4h)-酮的方法
CN113106473B (zh) * 2021-04-14 2022-02-18 南京工业大学 一种通过连续电化学微反应器装置制备1,3-苯并噁嗪衍生物的方法
WO2023064196A1 (en) * 2021-10-15 2023-04-20 Merck Sharp & Dohme Llc Benzoxazinone derivatives as selective cytotoxic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526621A (en) * 1966-08-03 1970-09-01 Farmaceutical Italia Soc Substituted 3,1-benzoxazin-2-one
US3562621A (en) * 1967-07-26 1971-02-09 Technipower Inc Inrush current limiting circuit for rectifier circuits with capacitive load
DE3217012A1 (de) * 1982-05-06 1983-11-10 Dr. Karl Thomae Gmbh, 7950 Biberach Benzoxazin-2-one, deren herstellung und diese verbindungen enthaltende arzneimittel
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
IL99843A0 (en) * 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors

Also Published As

Publication number Publication date
YU53093A (sh) 1996-10-09
ES2151897T3 (es) 2001-01-16
HRP931102B1 (en) 2001-06-30
LV12719A (lv) 2001-09-20
DE69329608D1 (de) 2000-12-07
BG62612B1 (bg) 2000-03-31
JPH06184124A (ja) 1994-07-05
NZ255216A (en) 1996-05-28
AU4449693A (en) 1994-02-10
NO2008008I1 (no) 2008-06-30
CN1318031C (zh) 2007-05-30
CA2101572A1 (en) 1994-02-08
CN1250652A (zh) 2000-04-19
NO950424D0 (no) 1995-02-06
EP0582455B1 (en) 2000-11-02
WO1994003440A1 (en) 1994-02-17
LV12719B (lv) 2001-12-20
DE10199013I1 (de) 2001-05-23
JPH0780860B2 (ja) 1995-08-30
DZ1707A1 (fr) 2002-02-17
IL106507A0 (en) 1993-11-15
FI950508A0 (fi) 1995-02-06
NO2000004I1 (no) 2000-06-16
CN1090277A (zh) 1994-08-03
RU2186775C2 (ru) 2002-08-10
KR950702970A (ko) 1995-08-23
HRP931102A2 (en) 1997-10-31
SG52698A1 (en) 1998-09-28
MX192812B (es) 1999-07-30
CA2101572C (en) 2001-08-28
KR100272387B1 (ko) 2000-11-15
CN1107505C (zh) 2003-05-07
YU49439B (sh) 2006-03-03
CN1221608A (zh) 1999-07-07
TW382014B (en) 2000-02-11
DE122008000034I1 (de) 2008-10-02
DE10199013I2 (de) 2007-05-24
LU90709I2 (fr) 2002-02-04
BG99383A (bg) 1995-09-29
FI115457B (fi) 2005-05-13
GR3034754T3 (en) 2001-02-28
HUT71219A (en) 1995-11-28
SI9300419A (en) 1994-06-30
PL176679B1 (pl) 1999-07-30
HU223076B1 (hu) 2004-03-01
MX9304775A (es) 1994-05-31
DE69329608T2 (de) 2001-05-03
IL106507A (en) 1997-11-20
RO113641B1 (ro) 1998-09-30
CZ290447B6 (cs) 2002-07-17
UA42699C2 (uk) 2001-11-15
RU95107403A (ru) 1996-11-20
SK16195A3 (en) 1995-07-11
SI9300419B (sl) 2002-10-31
SK282276B6 (sk) 2002-01-07
ATE197295T1 (de) 2000-11-15
NL300347I1 (nl) 2008-07-01
AU670300B2 (en) 1996-07-11
FI950508A (fi) 1995-02-06
NL300032I1 (no) 2001-02-01
CN1051767C (zh) 2000-04-26
MY109834A (en) 1997-08-30
PT582455E (pt) 2001-03-30
EP0582455A1 (en) 1994-02-09
NO304886B1 (no) 1999-03-01
CZ28695A3 (en) 1995-09-13
HU9500366D0 (en) 1995-03-28
PL175615B1 (pl) 1999-01-29
LU91446I2 (fr) 2008-07-28
TWI233436B (en) 2005-06-01
PL307348A1 (en) 1995-05-15
DK0582455T3 (da) 2000-11-27
HK1009267A1 (en) 1999-05-28
NL300032I2 (nl) 2001-04-02

Similar Documents

Publication Publication Date Title
NO950424D0 (no) Benzoxazinoner som inhibitorer av HIV reverstranskriptase
ATE175412T1 (de) Hiv-protease-inhibitoren
MX9700036A (es) Combinacion de compuestos, uso en la preparacion de composiciones para tratar infeccion por el vir s de inmunodeficiencia humana, y composiciones obtenidas.
DK0774969T3 (da) HIV-proteaseinhibitor kombination

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: ATRIPLA TABLETT, FILMDRASJERT 600MG/ 200 MG/ 245 MG; NAT. REG. NO/DATE: EU/1/07/430/001/NO 20080129; FIRST REG. NO/DATE: EU , EU/1/07/430/001 20071213

Spc suppl protection certif: 2008008

Filing date: 20080612

MK1K Patent expired
SPCX Expiry of an spc

Free format text: PRODUCT NAME: EFAVIRENZ, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: NO , 98/6875, 98/6876, 98/6877 19991216; FIRST REG. NO/DATE: CH , IKS-54 908 19981120

Spc suppl protection certif: 2000004

Filing date: 20000616

Effective date: 20131120

SPCB Board of appeal decision concerning a supplementary protection certificate (spc)

Free format text: KLAGESAKEN HEVES

Spc suppl protection certif: 2008008

Filing date: 20121112

Effective date: 20180209

SPCW Withdrawal, rejection or dismissal of supplementary protection certificate

Spc suppl protection certif: 2008008